Ponatinib / AP24534 / 943319-70-8
| Post Date: |
Aug 18,2016 |
| Expiry Date: |
Aug 18,2017 |
| Detailed Description: |
Cas No. :943319-70-8
Specs:98%min
Payment Method: T/T
Ponatinib is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor.Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors. |
| CAS Registry Number: |
|
| Synonyms: |
;AP24534;AP24534(Ponatinib); |
| Molecular Formula: |
C29H27F3N6O |
| Molecular Weight: |
532.5595 |
| Molecular Structure: |
|
| Company: |
Shanghai Biopharmaleader Co.,Ltd
[ China ]
|
| Contact: |
Brenda Xu |
| Tel: |
021-50180596 |
| Fax: |
021-57758967 |
| Email: |
brenda@biopharmaleader.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
